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cases, 2,376 hospitalizations, and 236 deaths. Associated influenza costs avoided 
were estimated at more than TRY 8.3 million, while the cost of vaccination would 
be more than TRY 8.4 million. The incremental cost-effectiveness ratio (ICER) was 
estimated at TRY 64/QALY, which is below the GDP per capita and very cost-effective. 
Factors most influencing the ICER were excess hospitalisation rate, inpatient cost, 
vaccine effectiveness against hospitalization, and attack rate. In addition, increas-
ing vaccination coverage rate to above 20% was also estimated to be very cost-
effective. ConClusions: Increasing the influenza vaccination coverage rate for 
adults with type 2 diabetes in Turkey to 20% or higher would be very cost-effective. 
To reduce influenza burden in diabetic patients, an integrated care approach is 
needed and all stakeholders need to cooperate to increase the vaccination coverage 
rates to WHO recommended levels.
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objeCtives: Insulin analogues offer certain advantages over regular human insu-
lin. Our objective was to establish the incremental cost-effectiveness ratio (ICER) 
of insulin analogues compared with human insulin, with multiple daily injections 
(MID) in adult patients with type 1 diabetes mellitus (DM1) in Colombia. Methods: 
We designed a Markov model of annual cycles, time horizon of up to 55 years, 
from a third-party payer perspective (only direct medical costs for the Colombian 
healthcare system) and applying discount rate of 3.5% both for costs and outcomes. 
Quality-adjusted life years (QALYs), taken from published literature, were used as 
a measure of effectiveness with a threshold of three times the per capita gross 
domestic product (GDP), approximately € 17,550. The comparison between analog 
and human insulin was performed separately for short and long term. The costs 
were in Colombian pesos (1 € = COP 2.660), and were built through base cases 
designed by interdisciplinary expert panels, with drug prices and costs of interven-
tions or adverse events were estimated using official tariff manuals and databases. 
Univariate and probabilistic sensitivity analysis were performed. Results: Despite 
certain clinical advantages, insulin analogues gain, on average, very few QALYs (from 
0.02 to 0.1 depending on scenarios). With this result, the average ICER for short-term 
insulins would be € 78,900; while long duration insulin analogues have an ICER of 
€ 94,550. Results were highly sensitive to price of medication, as well as to disutil-
ity or costs of hypoglycemic events. ConClusions: Given the assumptions and 
limitations of our model, insulin analogues would not be considered cost-effective 
within the Colombian healthcare system compared with multiple daily injections 
for adult patients with DM1.
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objeCtives: The objective is to describe disease progression and treatment pat-
terns of acromegaly in patients with inadequate biochemical control, assess how 
biochemical control will impact disease progression and treatment pathways and 
estimate the economic efficiency of pasireotide long-acting (PASI) in a treatment of 
acromegaly in Finland. PASI is compared to pegvisomant + somatostatin analoque 
(PEG+SSA) in patients with inadequately controlled acromegaly. Methods: A 
5-state Markov model describing the disease progression and management of 
acromegaly was constructed. The model enables an assessment of how biochemi-
cal control associated with PASI is translated into Quality Adjusted Life Years 
(QALYs), costs and subsequently incremental cost-effectiveness ratio. Transition 
probabilities were determined by clinical trial data (study 2402) in 6 month cycles. 
Achievement of control has an impact on quality of life, mortality risk and preva-
lence of comorbidities, whereas achievement of tumor reduction will have an 
impact on quality of life. Utilities for each health state were derived from the 2402 
trial and the literature. The annual visit, monitoring and comorbidity costs were 
estimated by treatment response and were based on patient level data (n= 66) 
from Auria biobank. The analysis was undertaken from health care payer perspec-
tive using 30-years time horizon. Results: PASI dominated PEG+SSA treatment 
strategy. PASI was associated with more than 100,000€ lower costs compared to 
PEG+SSA. This is primarily driven by the lower pharmaceutical cost.PASI patients 
were on average 0.19 more years in biochemical control compared with PEG+SSA 
and was associated with QALY gain of 0.02. The difference in QALYs result from 
the tumor reduction achieved with PASI as well as the drop-out rate due to liver 
toxicities occurring in PEG+SSA strategy. ConClusions: PASI provides a valu-
able addition to the treatment options for patients with acromegaly and can 
achieve mortality as well as morbidity improvements in a cost-effective way in 
Finland.
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objeCtives: Evaluate the cost analysis of fix dose combination of dapagliflozin 
plus metformin (DAPA+MET) compared with glipizide plus metformin (SU+MET), 
in the treatment of type 2 diabetes mellitus during one year. Methods: A ran-
adherence to medication (with insuficient local information). ConClusions: 
Sulfonylureas, other than glibenclamide, DPP-4 inhibitors and thiazolidinediones 
are cost-effective alternatives as second-line treatment for DM2 patients that 
require oral antidiabetics in Colombia. Patient adherence requires further local 
research.
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objeCtives: To estimate cost-effectiveness of exenatide twice daily (BID) versus 
insulin glargine once daily (QD) as add-on therapy in Chinese type 2 diabetes 
patients not well controlled by oral anti-diabetic (OAD) agents. Methods: The 
Cardiff model was populated with the data synthesized from three head-to-head 
randomized clinical trials up to 30 weeks in China comparing exenatide BID vs 
insulin glargine as add-on therapies to oral therapies in the Chinese population. 
The Cardiff model generated outputs including macrovascular and microvascular 
complications, diabetes-specific mortality, costs and quality-adjusted life years 
(QALYs). Cost and QALYs were estimated with time horizon of 40 years at a dis-
count rate of 3% from the societal perspective Results: Compared with insulin 
glargine plus OAD treatments, patients on exenatide BID plus OAD gained 1.88 
QALYs, at an incremental cost saving of Chinese Renminbi (RMB) 114,593 (i.e., cost 
saving of RMB 61078/QALY). The cost-effectiveness results were robust to vari-
ous sensitivity analyses including probabilistic sensitivity analysis. The variables 
with the most impact on incremental cost-effectiveness ratio included HbA1c 
level at baseline, health utilities decrement and BMI at baseline. ConClusions: 
Compared with Insulin glargine QD, exenatide BID as add-on therapy to OAD is a 
cost-effective treatment in the Chinese patients inadequately controlled by OAD 
treatments.
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objeCtives: Diabetes mellitus type 2 is a chronic disease, with many issues both 
in terms of pathophysiology and therapy; its incidence is steadily increasing, in 
line with the increase of the aging population. For this reason, diabetes could 
be considered an emergency also for its economic burden. Methods: We per-
formed a cost minimization analysis to evaluate the impact of different treat-
ments on patients with type 2 diabetes, kidney failure, on dialysis, from moderate 
to severe stage, who failed monotherapy with metformin. We considered direct 
and indirect costs: the resources consumed in providing facilities and those 
used to counter the negative effects of the different treatments, and produc-
tion losses of patients. Results: We compared the following hypoglycemic mol-
ecules: Pioglitazone (15, 30), Repaglinide (0.5, 1, 2), Vildagliptin50 and Linagliptin5. 
Regarding insulin therapy, we consider the following classifications: Insulins 
human, Basal analogs and Fast analogs. An analysis of the direct medical costs 
of treatment and loss of production shows an average annual cost per patient 
treated with insulin between € 1,005.63 - € 1,098.34, with differentials cost vs. other 
hypoglycemic strategies between € 174 and € 203. The cost for the management 
of hypoglycemia is greatest with the insulin treatment but with a limited impact 
on the total cost of health care and treatment. The loss of working days due to 
treatment and to hypoglycemic episodes have a considerable impact (71% of the 
total cost). The total cost related to a treatment with of Vildagliptin is in line with 
that of other strategies. Furthermore Vildagliptin has a lower economic impact, 
if taken into account indirect costs. ConClusions: The cost analysis of therapy 
applied to diabetes demonstrates that the use of Vildagliptin represents a choice, 
that is economically favorable if we consider the whole diabetic population costs, 
including renal insufficiency patients.
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objeCtives: Influenza triggers high risk of complications in patients with diabetes. 
Influenza vaccination is safe and effective in diabetic patients. In Turkey, the preva-
lence of diabetes is high but the influenza vaccination coverage rate is low, 9.1% in 
2014, despite vaccination being recommended and reimbursed in this population. 
This study therefore, evaluated the cost-effectiveness of increasing the influenza 
vaccination coverage rate of adults aged ≥ 18 years with type 2 diabetes in Turkey 
to 20%. Methods: A decision-analytic model was adapted to Turkey using data 
derived from published sources. Based on the literature, patients with diabetes 
have a 6-fold increase in influenza-related hospitalization and 3-fold increase in 
influenza-related death compared to healthy individuals. Direct medical costs and 
indirect costs due to productivity loss were included in the societal perspective. 
Costs were calculated in Turkish Lira (TRY) (0.43 per US dollar in 2014). A one-year 
time horizon was set to reflect influenza seasonality. Results: Increasing the 
influenza vaccination coverage rate to 20% is predicted to avert 19,777 influenza 
